In the HER2 + TCHL WXS cohort here, we first individually assessed which clinicopathological and genomic features extracted from WXS data generated from pre-treatment tumour biopsies, may be associated with therapy response (Fig. 5a, Supplementary Table 8). This evidence concerns the gene ERBB2 and neoplasm.